Oral GLP-1 Diabetes Therapy Shock: FDA Clears ASC30 for Human Trials  

Ascletis Pharma Inc. announced a major step forward in diabetes therapy innovation. The Food and Drug Administration granted Investigational New Drug clearance for ASC30. The FDA cleared a 13-week Phase II clinical trial for oral GLP-1 diabetes therapy. The trial will test Ascletis’ oral small-molecule GLP-1 receptor agonist, ASC30.

The study will enroll adults with type 2 diabetes. This trial could shift how doctors treat diabetes. ASC30 may offer a pill alternative to injectable medications. Many patients have relied on injectable treatments for years.

The upcoming Phase II study will be a randomized, double-blind, placebo-controlled, and multi-center trial. The trial will test ASC30 in adults with type 2 diabetes. It will evaluate the drug’s efficacy and will also assess safety.
The study will measure tolerability over 13 weeks.

Participants will be randomly assigned in the study. They will receive one of three ASC30 doses: 40 mg, 60 mg, or 80 mg. Some participants will receive a matched placebo.

Researchers will titrate doses weekly from 1 mg to the target dose. They expect to start enrollment in the first quarter of 2026 at multiple clinical sites.

The trial’s primary endpoint is the change in HbA1c, a key marker of long-term blood sugar control. Secondary measures include changes in fasting blood glucose, body weight, and assessments of safety and tolerability.

GLP-1 (glucagon-like peptide-1) receptor agonists have transformed diabetes care over the past decade. They help the body release insulin when needed, lower blood sugar, and often support weight loss. Until recently, most of these drugs have been injectable. An effective oral version would appeal to many people who prefer pills over injections.

ASC30 is part of a new generation of small-molecule GLP-1 therapies that aim to make treatment simpler and more convenient. ASC30 differs from larger peptide-based GLP-1 drugs like semaglutide or tirzepatide. It was developed to work when taken orally. Oral delivery may support broader patient access and better adherence.

Ascletis previously conducted a 13-week Phase II study of ASC30 in people with obesity or overweight, and the results were encouraging. In that trial, the drug delivered statistically significant, dose-dependent weight loss compared with placebo, with mean reductions of 5.4%, 7.0%, and 7.7% body weight at doses of 20 mg, 40 mg, and 60 mg, respectively. Notably, investigators did not observe a plateau in weight loss during the study.

The drug also showed better gastrointestinal tolerability than some other GLP-1 small molecules, with lower rates of nausea and vomiting in the dose-escalation design. The overall discontinuation rate due to side effects was 4.8% in that trial.

These early outcomes add confidence as Ascletis now pivots toward diabetes. Many peptide GLP-1 receptor agonists cannot be taken orally. ASC30 is a small molecule that targets the GLP-1 receptor without injections.
The drug was developed for once-daily oral dosing. It also has once-monthly to once-quarterly subcutaneous injection options. ASC30 aims to treat obesity, diabetes, and other metabolic diseases.

Researchers designed ASC30 to be a biased agonist. It activates certain GLP-1 receptor pathways more selectively. This may enhance the drug’s effects. It may also reduce some side effects.

The diabetes drug market is one of the largest in healthcare, and GLP-1 therapies have driven major shifts in treatment standards. Yet many of the established options still require weekly or daily injections. 

A widely effective oral GLP-1 therapy could improve patient convenience and acceptance, particularly for those with needle anxiety or lifestyle barriers to regular injections.

Other companies have advanced oral GLP-1 molecules in development. For example, orforglipron has shown clinical promise in recent trials testing glycemic control and weight loss, although it remains investigational. ASC30’s unique profile and flexible dosing options may set it apart if ongoing studies uphold safety and efficacy.

If Ascletis’ Phase II study succeeds, the company could advance to larger Phase III studies and, eventually, seek FDA approval for marketing. That would put an oral GLP-1 option within reach of many Americans struggling with type 2 diabetes.

Ascletis plans to begin enrollment for the diabetes Phase II trial in early 2026. The company will monitor changes in blood sugar control, weight, and safety over the 13-week period. Results from this study will determine whether ASC30 can proceed to larger studies and seek regulatory approval in diabetes.

This trial represents an important experiment in oral small-molecule drugs. It could reshape chronic disease treatment. The study offers patients a less invasive way to manage type 2 diabetes.